X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (830) 830
phthalazines - therapeutic use (621) 621
index medicus (524) 524
female (497) 497
male (370) 370
animals (340) 340
phthalazines - pharmacology (321) 321
oncology (274) 274
middle aged (246) 246
phthalazines - administration & dosage (245) 245
adult (237) 237
piperazines - therapeutic use (220) 220
cancer (190) 190
antineoplastic agents - therapeutic use (179) 179
mice (169) 169
piperazines - pharmacology (166) 166
aged (163) 163
poly polymerase (163) 163
cell line, tumor (159) 159
mutation (150) 150
phthalazines - adverse effects (146) 146
pharmacology & pharmacy (140) 140
ovarian neoplasms - drug therapy (136) 136
poly polymerase inhibitors (130) 130
olaparib (123) 123
treatment outcome (122) 122
tumors (116) 116
dna repair (114) 114
ovarian cancer (107) 107
breast cancer (106) 106
chemotherapy (104) 104
double-blind method (101) 101
poly polymerase inhibitors - therapeutic use (98) 98
ovarian neoplasms - genetics (95) 95
piperazines - administration & dosage (95) 95
histamine h1 antagonists - therapeutic use (92) 92
dna damage (90) 90
poly polymerase inhibitors - pharmacology (90) 90
antineoplastic agents - pharmacology (87) 87
antineoplastic combined chemotherapy protocols - therapeutic use (83) 83
rats (83) 83
analysis (82) 82
deoxyribonucleic acid--dna (81) 81
homologous recombination (81) 81
adolescent (80) 80
inhibition (76) 76
aldehyde reductase - antagonists & inhibitors (75) 75
azelastine (74) 74
research (74) 74
administration, intranasal (72) 72
brca1 protein - genetics (72) 72
pyridines - therapeutic use (72) 72
dose-response relationship, drug (70) 70
neoplasms - drug therapy (70) 70
rhinitis, allergic, seasonal - drug therapy (70) 70
therapy (70) 70
poly polymerases - metabolism (68) 68
article (67) 67
cancer therapies (67) 67
anti-allergic agents - therapeutic use (66) 66
repair (66) 66
allergy (65) 65
brca2 protein - genetics (65) 65
expression (65) 65
genes, brca1 (64) 64
parp inhibitor (64) 64
care and treatment (63) 63
piperazines - adverse effects (62) 62
breast neoplasms - drug therapy (61) 61
cell proliferation - drug effects (61) 61
xenograft model antitumor assays (61) 61
phthalazines - pharmacokinetics (60) 60
inhibitors (59) 59
clinical trials as topic (58) 58
genetic aspects (58) 58
phthalazines - chemistry (57) 57
angiogenesis (56) 56
genes, brca2 (56) 56
ribose (55) 55
angiogenesis inhibitors - therapeutic use (54) 54
immunology (54) 54
medicine, research & experimental (54) 54
clinical trials (53) 53
proteins (53) 53
cells (52) 52
ovarian neoplasms - pathology (52) 52
drug therapy (51) 51
monosaccharides (51) 51
sugars (51) 51
child (50) 50
disease models, animal (50) 50
biochemistry & molecular biology (49) 49
breast neoplasms - genetics (49) 49
cell survival - drug effects (49) 49
apoptosis - drug effects (48) 48
double-blind (48) 48
apoptosis (47) 47
cell biology (47) 47
mice, nude (47) 47
aged, 80 and over (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (937) 937
Japanese (24) 24
French (16) 16
German (10) 10
Russian (9) 9
Italian (6) 6
Chinese (5) 5
Polish (5) 5
Spanish (3) 3
Czech (2) 2
Hungarian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10043, pp. 518 - 529
Summary Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been validated as a target in several tumour types through randomised... 
Internal Medicine | PHASE-III TRIAL | ADVANCED HEPATOCELLULAR-CARCINOMA | BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | PANCREATIC NEUROENDOCRINE TUMORS | TYROSINE KINASE INHIBITOR | RECURRENT OVARIAN-CANCER | ANTI-ANGIOGENIC THERAPY | RESISTANT PROSTATE-CANCER | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Humans | Drug Resistance, Neoplasm | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Biomarkers, Tumor - metabolism | Female | Neovascularization, Pathologic - prevention & control | Molecular Targeted Therapy - methods | Receptor, TIE-2 - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Neoplasms - blood supply | Piperazines - therapeutic use | Angiopoietin-1 - antagonists & inhibitors | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Disease-Free Survival | Phthalazines - therapeutic use | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinolines - therapeutic use | Antimitotic agents | Pancreatic cancer | Melanoma | Neovascularization | Antineoplastic agents | Vascular endothelial growth factor | Prostate cancer | Cervical cancer | Drugs | Angiogenesis | Chemotherapy | Clinical trials | Oncology | Metastasis | Cancer therapies | Tumors | Cancer
Journal Article
Lung Cancer, ISSN 0169-5002, 12/2017, Volume 114, pp. 12 - 22
•SCLC is characterised by high proliferation and rapid development of chemo resistant disease.•SCLC is reliant on functional DNA damage repair pathways and... 
DNA Repair Pathways | Lung Cancer | Checkpoint Inhibitors | Small Cell Lung Cancer | PARP Inhibitors | TOPOISOMERASE-II-ALPHA | TUMOR-CELLS | AURORA KINASE | CELL LUNG-CANCER | WEE1 KINASE | ONCOLOGY | RESPIRATORY SYSTEM | HUMAN RAD51 PROTEIN | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | HOMOLOGOUS RECOMBINATION | PHASE-I | Lung Neoplasms - drug therapy | Humans | Rad51 Recombinase - antagonists & inhibitors | Aurora Kinases - therapeutic use | Small Cell Lung Carcinoma - drug therapy | Heterocyclic Compounds, 4 or More Rings - therapeutic use | DNA Damage - genetics | Genomic Instability - drug effects | Cell Cycle Checkpoints - genetics | Rad51 Recombinase - therapeutic use | Carbolines - therapeutic use | Genomic Instability - genetics | Molecular Targeted Therapy - methods | Benzimidazoles - therapeutic use | Cytotoxins - therapeutic use | DNA Damage - drug effects | Lung Neoplasms - genetics | Cell Proliferation - genetics | Etoposide - therapeutic use | Piperazines - therapeutic use | Small Cell Lung Carcinoma - genetics | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Azepines - therapeutic use | Phthalazines - therapeutic use | Cell Cycle Checkpoints - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | DNA Repair | Cell Proliferation - drug effects | Chemotherapy | DNA repair | Lung cancer | DNA damage | DNA | Cancer
Journal Article
Journal Article
by Bian, X and Gao, J and Luo, F and Rui, C and Zheng, T and Wang, D and Wang, Y and Roberts, T.M and Liu, P and Zhao, J.J and Cheng, H
Oncogene, ISSN 0950-9232, 01/2018, Volume 37, Issue 3, pp. 341 - 351
Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homologous recombination (HR)... 
POLY(ADP-RIBOSE) POLYMERASE | MUTANT-CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | PI3K INHIBITOR | CELL BIOLOGY | HOMOLOGOUS RECOMBINATION REPAIR | OLAPARIB | NUCLEAR PTEN | ONCOLOGY | PROSTATE-CANCER | GENETICS & HEREDITY | DNA-REPAIR | Humans | Endometrium - drug effects | Spheroids, Cellular - pathology | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms, Experimental - pathology | Aminopyridines - therapeutic use | Endometrial Neoplasms - genetics | Neoplasms, Experimental - genetics | Female | Spheroids, Cellular - drug effects | Recombinational DNA Repair - drug effects | Morpholines - therapeutic use | PTEN Phosphohydrolase - genetics | Carcinoma, Endometrioid - genetics | PTEN Phosphohydrolase - deficiency | Morpholines - pharmacology | Mice, Transgenic | Piperazines - therapeutic use | Carcinoma, Endometrioid - drug therapy | Piperazines - pharmacology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Phthalazines - therapeutic use | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | CRISPR-Cas Systems | Cell Line, Tumor | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Endometrium - pathology | Neoplasms, Experimental - drug therapy | Carcinoma, Endometrioid - pathology | Prevention | Phosphatases | Endometrial cancer | DNA damage | Therapeutics | Genetic aspects | Health aspects | Sugars | Cancer | Monosaccharides | Homeopathy | Materia medica and therapeutics | CRISPR | Tensin | Phosphorylation | BRCA1 protein | Homologous recombination | Poly(ADP-ribose) polymerase | RNA polymerase | Double-strand break repair | Kinases | DNA repair | 1-Phosphatidylinositol 3-kinase | DNA-dependent protein kinase | Ribose | Rodents | Non-homologous end joining | Tumor suppressor genes | PTEN protein | Deoxyribonucleic acid--DNA | Endometrium | Tumors | Original
Journal Article
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2008, Volume 105, Issue 44, pp. 17079 - 17084
Journal Article
Journal Article